AAA617 not checked
Novartis · Lu-PSMA-617 · 177Lu-PSMA-617
FollowEvery change as it happens, and a Monday email
Trials
18 active
24 in total · 21 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.”In the company’s words, NCT05803941 on ClinicalTrials.gov
- Tested for
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2 trials), Prostate Cancer, Prostatic Neoplasms, Oligometastatic Prostate Cancer (OMPC), Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostatic Neoplasm, Prostatic Cancer, Castration-Resistant, Metastatic Castration-Resistant Prostate Cancer
- Main trialPhase 4
- “The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.”In the company’s words, NCT05803941 on ClinicalTrials.gov
- Other names
- Lu-PSMA-617 · Pluvicto · 177Lu-PSMA-617
Other drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- PasritamigJohnson & Johnson (Janssen) · Phase 3
- JNJ-87189401Johnson & Johnson (Janssen) · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- JSB462Novartis · Phase 2
- GedatolisibCelcuity Inc · Phase 1/2
- TD001T.O.A.D. Oncology SA · Phase 1/2
Coming up5
- 23 DecPhase 2 trial completes · ClinicalTrials.gov
- 16 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 25 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 24 Apr 2029Phase 1 trial completes · ClinicalTrials.gov
- 20 Jul 2033Phase 4 trial completes · ClinicalTrials.gov
Changes4
Last 90 days- 17 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06379217
- 17 NovCompletion date moved: 2026-10-09 to 2026-10-16 · ClinicalTrials.gov NCT06379217
- 12 NovCompletion date moved: 2026-10-15 to 2026-11-17 · ClinicalTrials.gov NCT06894511
- 9 NovCompletion date moved: 2026-12-14 to 2026-11-06 · ClinicalTrials.gov NCT06004661
Trials24
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 20 Jul 2033 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | |
| Phase 3Active, not recruiting | 13 Jan 2025 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | |
| Phase 3Recruiting | 25 Apr 2028 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | |
| Phase 2Active, not recruiting | 2 Dec 2024 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | |
| Phase 2Active, not recruiting | 6 Nov 2026 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | |
| Phase 2Active, not recruiting | 17 Nov 2026 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | |
| Phase 2Active, not recruiting | 23 Dec 2026 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | |
| Phase 2Active, not recruiting | 16 Jul 2027 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | |
| Phase 1Active, not recruiting | 24 Apr 2029 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study | |
| Phase 3Completed | 2 Oct 2022 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | |
| Phase 2Completed | 17 May 2024 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | |
| Phase 1Terminated | 16 Oct 2026 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. | |
| Phase 1/2Authorised | not given | A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS) | |
| Phase 3Authorised | not given | PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC. | |
| Phase 2Ended | not given | The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial | |
| Phase 2Authorised | not given | 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregional teleradiotherapy and hormone therapy. | |
| Phase 2Ended | not given | Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. | |
| Phase 2Authorised | not given | ReaLuP : an open label, single arm phase IIb study of re-treatment with [177Lu]Lu-PSMA in men with metastatic castration resistance prostate cancer | |
| Phase 1Ended | not given | A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial) | |
| Phase 2Authorised | not given | EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT) | |
| Phase 3Authorised | not given | Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2) | |
| Phase 1Authorised | not given | An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC) | |
| Phase 2Authorised | not given | Phase 2, open-label, randomized study to investigate safety and efficacy of Pluvicto® therapy in patients with metastatic hormone-sensitive prostate cancer in addition to standard of care treatment with Nubeqa® and ADT (ARALU) | |
| Phase 2Authorised | not given | Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026